Declan Noone

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8226432/publications.pdf

Version: 2024-02-01

22	270	933447 10	940533 16
papers	citations	h-index	g-index

22	22	22	254
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Barriers and challenges faced by women with congenital bleeding disorders in Europe: Results of a patient survey conducted by the European Haemophilia Consortium. Haemophilia, 2019, 25, 468-474.	2.1	38
2	Delivery of AAVâ€based gene therapy through haemophilia centresâ€"A need for reâ€evaluation of infrastructure and comprehensive care: A Joint publication of EAHAD and EHC. Haemophilia, 2021, 27, 967-973.	2.1	29
3	Gene therapy to cure haemophilia: Is robust scientific inquiry the missing factor?. Haemophilia, 2020, 26, 931-933.	2.1	24
4	European principles of care for women and girls with inherited bleeding disorders. Haemophilia, 2021, 27, 837-847.	2.1	23
5	Hemophilia treatment in 2021: Choosing theâ€optimalâ€treatment using an integrative, patient-oriented approach to shared decision-making between patients and clinicians. Blood Reviews, 2022, 52, 100890.	5.7	22
6	Understanding minimum and ideal factor levels for participation in physical activities by people with haemophilia: An expert elicitation exercise. Haemophilia, 2020, 26, 711-717.	2.1	19
7	Nonâ€severe haemophilia: Is it benign? â€" Insights from the PROBE study. Haemophilia, 2021, 27, 17-24.	2.1	16
8	Psychometric properties of the Patient Reported Outcomes, Burdens and Experiences (PROBE) questionnaire. BMJ Open, 2018, 8, e021900.	1.9	15
9	Testâ€retest properties of the Patient Reported Outcomes, Burdens and Experiences (PROBE) questionnaire and its constituent domains. Haemophilia, 2019, 25, 75-83.	2.1	14
10	Eliminating Panglossian thinking in development of AAV therapeutics. Molecular Therapy, 2021, 29, 3325-3327.	8.2	12
11	Exploring regional variations in the crossâ€cultural, international implementation of the Patient Reported Outcomes Burdens and Experience (PROBE) study. Haemophilia, 2019, 25, 365-372.	2.1	11
12	Evolution of Haemophilia Care in Europe: 10 years of the principles of care. Orphanet Journal of Rare Diseases, 2020, 15, 184.	2.7	10
13	Vaccination against COVIDâ€19: Rationale, modalities and precautions for patients with haemophilia and other inherited bleeding disorders. Haemophilia, 2021, 27, 515-518.	2.1	9
14	Reimbursing the value of gene therapy care in an era of uncertainty. Haemophilia, 2021, 27, 12-18.	2.1	7
15	Clinical attributes and treatment characteristics are associated with work productivity and activity impairment in people with severe haemophilia A. Haemophilia, 2021, 27, 938-946.	2.1	7
16	Issues in assessing products for the treatment of hemophilia – the intersection between efficacy, economics, and ethics. Journal of Blood Medicine, 2015, 6, 185.	1.7	6
17	Recombinant factor IXâ€Fc fusion protein in severe hemophilia B: Patientâ€reported outcomes and healthâ€related quality of life. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12602.	2.3	4
18	Evaluation of the sexual health in people living with hemophilia. Haemophilia, 2021, 27, 993-1001.	2.1	2

#	Article	IF	Citations
19	Key challenges for hub and spoke models of care â€“ A report from the 1st workshop of the EHC Think Tank on Hub and Spoke Treatment Models. The Journal of Haemophilia Practice, 2022, 9, 20-26.	0.4	1
20	Patient agency: key questions and challenges â€“ A report from the 1st workshop of the EHC Think Tank Workstream on Patient Agency. The Journal of Haemophilia Practice, 2022, 9, 27-35.	0.4	1
21	Key challenges for patient registries â€“ A report from the 1st workshop of the EHC Think Tank Workstream on Registries. The Journal of Haemophilia Practice, 2022, 9, 14-19.	0.4	0
22	New challenges for an expanding generation of older persons with haemophilia. The Journal of Haemophilia Practice, 2022, 9, 1-13.	0.4	0